Core Viewpoint - The China Securities Regulatory Commission has confirmed the overseas listing applications for five companies, all of which are seeking to list in Hong Kong [1] Group 1: Company Summaries - **Lemo**: Plans to issue up to 19,166,700 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Lemo is a machine massage service provider with over 48,000 service points and more than 535,000 massage machines deployed as of July 18, 2025. Revenue for 2022 to 2024 is projected at 330 million, 587 million, and 798 million CNY, with corresponding net profits of 6.48 million, 87.34 million, and 85.81 million CNY [3][5] - **Dipu**: Plans to issue up to 115,000,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Dipu focuses on providing AI solutions, including big data analysis and enterprise-level model applications, across various sectors. Revenue for 2022 to 2024 is projected at 100 million, 129 million, and 243 million CNY, with corresponding net losses of 655 million, 503 million, and 1.255 billion CNY [5][7] - **Red Star Cold Chain**: Plans to issue up to 26,752,000 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Red Star Cold Chain operates a platform for frozen food trading and storage services. Revenue for 2022 to 2024 is projected at 237 million, 202 million, and 234 million CNY, with corresponding net profits of 79 million, 75 million, and 83 million CNY [7][9] - **Sailis**: Plans to issue up to 331,477,235 ordinary shares for overseas listing on the Hong Kong Stock Exchange. Sailis is a technology-driven automotive company focused on electric vehicles, having launched several models. Revenue for 2022 to 2024 is projected at 34.1 billion, 35.8 billion, and 145.1 billion CNY, with corresponding net losses of 5.2 billion, 4.2 billion, and a net profit of 4.7 billion CNY [9][11] - **Yiteng Pharmaceutical**: Plans to achieve a listing on the Hong Kong Stock Exchange through a merger with Genor Biopharma Holdings Limited, which will issue up to 1,883,972,094 ordinary shares. Yiteng focuses on the R&D, production, and commercialization of biopharmaceutical products across various therapeutic areas. Revenue for 2022 to 2024 is projected at 2.073 billion, 2.304 billion, and 2.546 billion CNY, with corresponding net profits of 306 million, 308 million, and 388 million CNY [11]